Copyright Reports & Markets. All rights reserved.

Global Tumor Necrosis Factor Inhibitors Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Tumor Necrosis Factor Inhibitors Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Tumor Necrosis Factor Inhibitors Market Size Growth Rate by Product
      • 1.4.2 Humira
      • 1.4.3 Enbrel
      • 1.4.4 Remicade
      • 1.4.5 Others
    • 1.5 Market by End User
      • 1.5.1 Global Tumor Necrosis Factor Inhibitors Market Size Growth Rate by End User
      • 1.5.2 Alzheimer's Diseases
      • 1.5.3 Parkinson's Diseases
      • 1.5.4 Ischemic Stroke
      • 1.5.5 Multiple Sclerosis
      • 1.5.6 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Tumor Necrosis Factor Inhibitors Market Size
      • 2.1.1 Global Tumor Necrosis Factor Inhibitors Revenue 2014-2025
      • 2.1.2 Global Tumor Necrosis Factor Inhibitors Sales 2014-2025
    • 2.2 Tumor Necrosis Factor Inhibitors Growth Rate by Regions
      • 2.2.1 Global Tumor Necrosis Factor Inhibitors Sales by Regions
      • 2.2.2 Global Tumor Necrosis Factor Inhibitors Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Tumor Necrosis Factor Inhibitors Sales by Manufacturers
      • 3.1.1 Tumor Necrosis Factor Inhibitors Sales by Manufacturers
      • 3.1.2 Tumor Necrosis Factor Inhibitors Sales Market Share by Manufacturers
      • 3.1.3 Global Tumor Necrosis Factor Inhibitors Market Concentration Ratio (CR5 and HHI)
    • 3.2 Tumor Necrosis Factor Inhibitors Revenue by Manufacturers
      • 3.2.1 Tumor Necrosis Factor Inhibitors Revenue by Manufacturers (2014-2019)
      • 3.2.2 Tumor Necrosis Factor Inhibitors Revenue Share by Manufacturers (2014-2019)
    • 3.3 Tumor Necrosis Factor Inhibitors Price by Manufacturers
    • 3.4 Tumor Necrosis Factor Inhibitors Manufacturing Base Distribution, Product Types
      • 3.4.1 Tumor Necrosis Factor Inhibitors Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Tumor Necrosis Factor Inhibitors Product Type
      • 3.4.3 Date of International Manufacturers Enter into Tumor Necrosis Factor Inhibitors Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Tumor Necrosis Factor Inhibitors Sales by Product
    • 4.2 Global Tumor Necrosis Factor Inhibitors Revenue by Product
    • 4.3 Tumor Necrosis Factor Inhibitors Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Tumor Necrosis Factor Inhibitors Breakdown Data by End User

    6 North America

    • 6.1 North America Tumor Necrosis Factor Inhibitors by Countries
      • 6.1.1 North America Tumor Necrosis Factor Inhibitors Sales by Countries
      • 6.1.2 North America Tumor Necrosis Factor Inhibitors Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Tumor Necrosis Factor Inhibitors by Product
    • 6.3 North America Tumor Necrosis Factor Inhibitors by End User

    7 Europe

    • 7.1 Europe Tumor Necrosis Factor Inhibitors by Countries
      • 7.1.1 Europe Tumor Necrosis Factor Inhibitors Sales by Countries
      • 7.1.2 Europe Tumor Necrosis Factor Inhibitors Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Tumor Necrosis Factor Inhibitors by Product
    • 7.3 Europe Tumor Necrosis Factor Inhibitors by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Tumor Necrosis Factor Inhibitors by Countries
      • 8.1.1 Asia Pacific Tumor Necrosis Factor Inhibitors Sales by Countries
      • 8.1.2 Asia Pacific Tumor Necrosis Factor Inhibitors Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Tumor Necrosis Factor Inhibitors by Product
    • 8.3 Asia Pacific Tumor Necrosis Factor Inhibitors by End User

    9 Central & South America

    • 9.1 Central & South America Tumor Necrosis Factor Inhibitors by Countries
      • 9.1.1 Central & South America Tumor Necrosis Factor Inhibitors Sales by Countries
      • 9.1.2 Central & South America Tumor Necrosis Factor Inhibitors Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Tumor Necrosis Factor Inhibitors by Product
    • 9.3 Central & South America Tumor Necrosis Factor Inhibitors by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Tumor Necrosis Factor Inhibitors by Countries
      • 10.1.1 Middle East and Africa Tumor Necrosis Factor Inhibitors Sales by Countries
      • 10.1.2 Middle East and Africa Tumor Necrosis Factor Inhibitors Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Tumor Necrosis Factor Inhibitors by Product
    • 10.3 Middle East and Africa Tumor Necrosis Factor Inhibitors by End User

    11 Company Profiles

    • 11.1 EPIRUS Biopharmaceuticals
      • 11.1.1 EPIRUS Biopharmaceuticals Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Products Offered
      • 11.1.5 EPIRUS Biopharmaceuticals Recent Development
    • 11.2 Bionovis
      • 11.2.1 Bionovis Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Bionovis Tumor Necrosis Factor Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Bionovis Tumor Necrosis Factor Inhibitors Products Offered
      • 11.2.5 Bionovis Recent Development
    • 11.3 CASI Pharmaceuticals
      • 11.3.1 CASI Pharmaceuticals Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Products Offered
      • 11.3.5 CASI Pharmaceuticals Recent Development
    • 11.4 Janssen Biotech
      • 11.4.1 Janssen Biotech Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Janssen Biotech Tumor Necrosis Factor Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Janssen Biotech Tumor Necrosis Factor Inhibitors Products Offered
      • 11.4.5 Janssen Biotech Recent Development
    • 11.5 Momenta Pharmaceuticals
      • 11.5.1 Momenta Pharmaceuticals Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Products Offered
      • 11.5.5 Momenta Pharmaceuticals Recent Development
    • 11.6 GlaxoSmithKline
      • 11.6.1 GlaxoSmithKline Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 GlaxoSmithKline Tumor Necrosis Factor Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 GlaxoSmithKline Tumor Necrosis Factor Inhibitors Products Offered
      • 11.6.5 GlaxoSmithKline Recent Development
    • 11.7 HanAll Biopharma
      • 11.7.1 HanAll Biopharma Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 HanAll Biopharma Tumor Necrosis Factor Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 HanAll Biopharma Tumor Necrosis Factor Inhibitors Products Offered
      • 11.7.5 HanAll Biopharma Recent Development
    • 11.8 Intas Pharmaceuticals
      • 11.8.1 Intas Pharmaceuticals Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Products Offered
      • 11.8.5 Intas Pharmaceuticals Recent Development
    • 11.9 LEO Pharma
      • 11.9.1 LEO Pharma Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 LEO Pharma Tumor Necrosis Factor Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 LEO Pharma Tumor Necrosis Factor Inhibitors Products Offered
      • 11.9.5 LEO Pharma Recent Development
    • 11.10 Dexa Medica
      • 11.10.1 Dexa Medica Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 Dexa Medica Tumor Necrosis Factor Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 Dexa Medica Tumor Necrosis Factor Inhibitors Products Offered
      • 11.10.5 Dexa Medica Recent Development
    • 11.11 LG Life Sciences
    • 11.12 MedImmune

    12 Future Forecast

    • 12.1 Tumor Necrosis Factor Inhibitors Market Forecast by Regions
      • 12.1.1 Global Tumor Necrosis Factor Inhibitors Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Tumor Necrosis Factor Inhibitors Revenue Forecast by Regions 2019-2025
    • 12.2 Tumor Necrosis Factor Inhibitors Market Forecast by Product
      • 12.2.1 Global Tumor Necrosis Factor Inhibitors Sales Forecast by Product 2019-2025
      • 12.2.2 Global Tumor Necrosis Factor Inhibitors Revenue Forecast by Product 2019-2025
    • 12.3 Tumor Necrosis Factor Inhibitors Market Forecast by End User
    • 12.4 North America Tumor Necrosis Factor Inhibitors Forecast
    • 12.5 Europe Tumor Necrosis Factor Inhibitors Forecast
    • 12.6 Asia Pacific Tumor Necrosis Factor Inhibitors Forecast
    • 12.7 Central & South America Tumor Necrosis Factor Inhibitors Forecast
    • 12.8 Middle East and Africa Tumor Necrosis Factor Inhibitors Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Tumor Necrosis Factor Inhibitors Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      The global Tumor Necrosis Factor Inhibitors market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Tumor Necrosis Factor Inhibitors market based on company, product type, end user and key regions.

      This report studies the global market size of Tumor Necrosis Factor Inhibitors in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Tumor Necrosis Factor Inhibitors in these regions.
      This research report categorizes the global Tumor Necrosis Factor Inhibitors market by top players/brands, region, type and end user. This report also studies the global Tumor Necrosis Factor Inhibitors market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      EPIRUS Biopharmaceuticals
      Bionovis
      CASI Pharmaceuticals
      Janssen Biotech
      Momenta Pharmaceuticals
      GlaxoSmithKline
      HanAll Biopharma
      Intas Pharmaceuticals
      LEO Pharma
      Dexa Medica
      LG Life Sciences
      MedImmune

      Market size by Product
      Humira
      Enbrel
      Remicade
      Others
      Market size by End User
      Alzheimer's Diseases
      Parkinson's Diseases
      Ischemic Stroke
      Multiple Sclerosis
      Others

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Tumor Necrosis Factor Inhibitors market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Tumor Necrosis Factor Inhibitors market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Tumor Necrosis Factor Inhibitors companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Tumor Necrosis Factor Inhibitors submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Tumor Necrosis Factor Inhibitors are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Tumor Necrosis Factor Inhibitors market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now